Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 4/20 | 0.53 |
| ▸ | IKBKB | O14920 | 1/20 | 0.53 |
| ▸ | RAF1 | P04049 | 1/20 | 0.53 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | AKT1 | P31749 | 1/20 | 0.53 |
| ▸ | AKT2 | P31751 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.53 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.53 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.53 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.53 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.53 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.53 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | MITF | O75030 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3583600 | 1.00 | MIF (0.53) | MIFIKBKBRAF1RPS6KB1MAPK1 | |
| SCHEMBL31518797 | 0.81 | ACHE (0.62) | IKBKBRAF1RPS6KB1MAPK1AKT1 | |
| SCHEMBL7130300 | 0.80 | IKBKB (0.63) | IKBKBRAF1RPS6KB1MAPK1AKT1 | |
| SCHEMBL21232790 | 0.80 | DYRK2 (0.63) | IKBKBRAF1RPS6KB1MAPK1AKT1 | |
| SCHEMBL31518792 | 0.80 | IKBKB (0.63) | IKBKBRAF1RPS6KB1MAPK1AKT1 | |
| SCHEMBL11608745 | 0.80 | DYRK2 (0.63) | IKBKBRAF1RPS6KB1MAPK1AKT1 | |
| SCHEMBL12443309 | 0.80 | HSD11B1 (0.67) | IKBKBRAF1RPS6KB1MAPK1AKT1 | |
| SCHEMBL3567965 | 0.80 | IKBKB (0.63) | IKBKBRAF1RPS6KB1MAPK1AKT1 | |
| SCHEMBL11608742 | 0.80 | DYRK2 (0.63) | IKBKBRAF1RPS6KB1MAPK1AKT1 | |
| SCHEMBL31518774 | 0.79 | IKBKB (0.51) | IKBKBRAF1RPS6KB1MAPK1AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6664272-B2 | Such as 1,5-Bis-(2, 4-difluorophenyl)penta-1,4-diene-3 -one; administering to inhibit tissue factor and vascular endothelial growth factor (VEGF) production in cancerous tissue | EMORY UNIVERSITY | 2003-12-16 | — | — | US | claimed |
| US-7842705-B2 | Curcumin analogs with anti-tumor and anti-angiogenic properties | EMORY UNIVERSITY (US) | 2010-11-30 | — | — | US | disclosed |
| US-20080234320-A1 | CURCUMIN ANALOGS WITH ANTI-TUMOR AND ANTI-ANGIOGENIC PROPERTIES | EMORY UNIVERSITY | 2008-09-25 | — | — | US | disclosed |
| US-7371766-B2 | Curcumin analogs with anti-tumor and anti-angiogenic properties | EMORY UNIVERSITY (US) | 2008-05-13 | — | — | US | disclosed |
| US-20050069551-A1 | Cytotoxic compound-protein conjugates as suppressors of tumor growth and angiogenesis | EMORY UNIVERSITY | 2005-03-31 | — | — | US | disclosed |
| US-20040176384-A1 | Curcumin analogs with anti-tumor and anti-angiogenic properties | EMORY UNIVERSITY | 2004-09-09 | — | — | US | disclosed |
| US-6664272-B2 | Such as 1,5-Bis-(2, 4-difluorophenyl)penta-1,4-diene-3 -one; administering to inhibit tissue factor and vascular endothelial growth factor (VEGF) production in cancerous tissue | EMORY UNIVERSITY | 2003-12-16 | — | — | US | disclosed |
| US-20020019382-A1 | Curcumin analogs with anti-tumor and anti-angiogenic properties | EMORY UNIVERSITY | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176384-A1 | Curcumin analogs with anti-tumor and anti-angiogenic properties | PGF, VEGFA, VHL | MIF 284/4885IKBKB 178/4885RAF1 4090/4885 |
| US-20050069551-A1 | Cytotoxic compound-protein conjugates as suppressors of tumor growth and angiogenesis | VEGFA, AGER, HDGF | MIF 1525/4885IKBKB 1354/4885RAF1 2562/4885 |
| US-20080234320-A1 | CURCUMIN ANALOGS WITH ANTI-TUMOR AND ANTI-ANGIOGENIC PROPERTIES | PGF, VEGFA, VHL | MIF 284/4885IKBKB 178/4885RAF1 4090/4885 |
| US-20020019382-A1 | Curcumin analogs with anti-tumor and anti-angiogenic properties | PGF, VEGFA, VHL | MIF 284/4885IKBKB 178/4885RAF1 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.